Research Updates

Back to feed
PubMed
Single case report

High importance

Sep 27, 2026

Severe Recurrent Gastrointestinal Bleeding Leading to the Diagnosis of Hereditary Hemorrhagic Telangiectasia: Clinical Response to Systemic Bevacizumab in a Case Report and Narrative Review.

View original source

Why it matters

Highlighting the effectiveness of bevacizumab in HHT-related gastrointestinal bleeding may provide an alternative treatment option for patients with recurrent bleeding, improving quality of life and reducing hospitalizations.

Objective

To report the effectiveness of systemic bevacizumab in managing severe gastrointestinal bleeding in a patient with hereditary hemorrhagic telangiectasia (HHT).

Results

The patient experienced a significant reduction in gastrointestinal bleeding episodes, with only three hospitalizations related to bleeding in the year following treatment compared to eleven prior to therapy. There was a noted qualitative endoscopic improvement in the appearance of gastric telangiectases, and no major adverse effects from bevacizumab were reported.

Methods

A 62-year-old woman with a history of recurrent epistaxis and gastrointestinal bleeding due to HHT was treated with intravenous bevacizumab (5 mg/kg) every 15 days for six cycles, followed by monthly maintenance therapy. Clinical outcomes and hospitalization rates for bleeding were monitored over a year post-treatment.

Limitations

This case report lacks a control group and involves only a single patient, limiting the generalizability of the results. Further research with larger populations and controlled trials are needed to confirm efficacy and safety.

For your doctor:

PMID: 42808060

DOI: 10.7759/cureus.117000

Abstract

Hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber disease, is an inherited vascular disorder that may cause severe gastrointestinal bleeding, particularly at an advanced age. The management of diffuse and recurrent gastrointestinal involvement may remain challenging despite repeated endoscopic treatments. We report the case of a 62-year-old woman with recurrent epistaxis since childhood, nasal and cutaneous telangiectases, and severe recurrent gastrointestinal bleeding related to multiple gastric, duodenal, jejunal, and more distal small-bowel telangiectases. A definite diagnosis of HHT was established based on the presence of three Curaçao criteria. During the two years preceding systemic therapy, the patient required 11 hospitalizations, repeated packed red blood cell transfusions, intravenous iron infusions, and 13 sessions of argon plasma coagulation. Intravenous bevacizumab was initiated at a dose of 5 mg/kg every 15 days for six induction cycles, followed by 5 mg/kg every four weeks as maintenance therapy. During one year of follow-up, the patient remained free of gastrointestinal bleeding for the first six months. The first recurrence occurred during the seventh month. Three separate hospitalizations for recurrent bleeding were observed during the year following bevacizumab initiation, compared with 11 during the preceding two years. The two most recent episodes were associated with less severe anemia than the most severe episodes before treatment. Qualitative endoscopic improvement, with an apparent reduction in the number and prominence of antral telangiectases, was also observed. No significant bevacizumab-related adverse events were identified. In this patient with severe HHT-related gastrointestinal involvement, systemic bevacizumab was associated with a clinically meaningful reduction in the overall bleeding burden. This case highlights the importance of considering HHT in patients with multiple or recurrent gastrointestinal telangiectases associated with epistaxis and mucocutaneous telangiectases.